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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To determine the efficacy and safety of gefitinib as first or second line treatment of advanced non-small cell lung cancer (NSCLC) by
undertaking the following comparisons:
a) Gefitinib at any dose compared with placebo or best supportive care for NSCLC
b) Gefitinib at any dose compared with other chemotherapeutic agents
c) Gefitinib at any dose in combination with other chemotherapeutic agents versus the same chemotherapy agents alone
d) Gefitinib at any dose in combination with other chemotherapeutic agents versus a different combination of chemotherapeutic agents
e) Gefitinib versus gefitinib combined with a chemotherapy regimen
B A C K G R O U N D
Lung cancer is a leading cause of cancer death in both men and
women worldwide. Lung cancer accounts for 31% and 27% of
cancer-related deaths in men and women respectively, based on
2005 estimates (ACS 2005). Therapy of non-small cell lung can-
cer (NSCLC) consists of surgery, radiotherapy and chemotherapy,
given as single therapies or in combination. Although there have
been major medical therapeutic advances in recent times, these
have not been sufficient to adequately affect the mortality and
morbidity rates associated with lung cancer. Approximately 60%
of patients will die of lung cancer within 1 year of diagnosis, and
70%-80% of patients will die within 2 years of diagnosis (ACS
2005).
The pathogenesis of lung neoplasms is multifactorial, however
it can mostly be directly attributed to tobacco smoke exposure.
NSCLC arising in smokers has a different spectrum of molecular
abnormalities than those seen in non-smokers, suggesting differ-
ences in molecular etiology, pathogenesis and possibly prognosis.
Mutations of tumour suppressor genes such as K-ras, p53 and
retinoblastoma; stimulation of proto-oncogenes such as c-myc and
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c-raf; and production of autocrine growth factors are some of the
pathogenetic mechanisms so far described in the development of
lung cancer.
The epidermal growth factor receptor (EGFR) family of genes
encodes a widely expressed transmembrane molecule that is fre-
quently expressed in solid tumours. The overexpression of EGFR
has been associated with the pathogenesis, proliferation, invasion
andmetastasis of various solid tumours, includingNSCLC. EGFR
is overexpressed in ~40-80% of documented cases of primary
NSCLC and ~88% of advanced cases of NSCLC (Smith 2005).
Tyrosine kinase inhibitors bind to the intracellular domain of the
tyrosine kinase and may inhibit EGFR downstream signalling. In-
hibition of tyrosine kinase may therefore block the EGFR-medi-
ated cancer cell propagation. These drugs may be distinguished as
reversible or irreversible tyrosine kinase inhibitors and as selective
against EGFR inhibitors or active against other members of the
family. Somatic mutations in the region of EGFR that encodes
the tyrosine kinase domain of the receptor (exons 18 through 21)
have been identified in lung cancer. Such mutations occur more
frequently in patients with adenocarcinoma, women, Asians, and
patients who have never smoked. (Kosaka 2004and Paez 2004)
EGFR mutations are associated with both increased growth fac-
tor signalling and increased responsiveness to tyrosine kinase in-
hibitors.
Gefitinib (Iressa, ZD 1839) is an orally active anilinoquinazoline
that selectively and reversibly inhibits intracellular EGFR tyro-
sine kinase activity. Two large phase II clinical trials (Fukuoka
2003 and Kris 2003) have assessed the efficacy and safety
of gefitinib monotherapy in patients with locally advanced or
metastatic NSCLC who failed previous chemotherapy regimens.
Both showed no added benefit in survival, time to progression
or response rates compared with standard chemotherapy alone.
However these monotherapy trials demonstrated a favourable sa-
fety profile. A phase III trial comparing gefitinib to placebo in
advanced NSCLC who received prior chemotherapy found no
benefits in survival, quality of life or symptom control (Thatcher
2005).
The efficacy of other EGFR inhibitors is also under investigation.
Erlotinib (Tarceva), is a potent reversible EGFR tyrosine kinase
inhibitor. It has been evaluated in a number of Phase III trials and
a protocol for the systematic review of these trials has been recently
published (Tort 2007). Other EGFR inhibitors such as CL-1033
and monoclonal antibodies against the EGFR such as cetuximab
and panitumumab are in varying stages of investigation for use in
advanced NSCLC.
O B J E C T I V E S
To determine the efficacy and safety of gefitinib as first or second
line treatment of advanced non-small cell lung cancer (NSCLC)
by undertaking the following comparisons:
a) Gefitinib at any dose compared with placebo or best supportive
care for NSCLC
b) Gefitinib at any dose compared with other chemotherapeutic
agents
c) Gefitinib at any dose in combination with other chemothera-
peutic agents versus the same chemotherapy agents alone
d) Gefitinib at any dose in combination with other chemothera-
peutic agents versus a different combination of chemotherapeutic
agents
e) Gefitinib versus gefitinib combined with a chemotherapy regi-
men
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will consider all published and unpublished controlled clin-
ical trials of gefitinib as first or second line therapy in advanced
NSCLC. We will include any placebo-controlled trials and trials
using comparators. Trials with random allocation, double-blind-
ing and intention-to-treat analysis will be preferred.
Crossover studies will be excluded. Studies that are quasi ran-
domised or have incomplete description of the randomisation pro-
cess will be excluded. Studies that investigated the compassionate
use of gefitinib will also be excluded.
Types of participants
The participants will be adult patients aged 18 years or older of
either sex with histologically or cytologically confirmed advanced
NSCLC (Stage III/IV).
Types of interventions
Any administration of gefitinib for advanced NSCLC will be con-
sidered. This includes the usage of any dosage of gefitinib as first
or second line therapy.
The following study designs will be included:
a) Gefitinib at any dose compared with placebo or best supportive
care for NSCLC
b) Gefitinib at any dose compared with other chemotherapeutic
agents
c) Gefitinib at any dose in combination with other chemothera-
peutic agents versus the same chemotherapy agents alone
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d) Gefitinib at any dose in combination with other chemothera-
peutic agents versus a different combination of chemotherapeutic
agents
e) Gefitinib versus gefitinib combined with a chemotherapy regi-
men
Types of outcome measures
The primary outcome will be survival, which is assessed from date
of randomisation to date of patient death (Time to death).Median
overall survival and survival at one year data will also be extracted
from included studies.
Secondary outcomes will include:
- Tumour response - classified according to Response Evaluation
Criteria in Solid Tumours (RECIST), the revised version of the In-
ternational UnionAgainst Cancer/WHOcriteria (Therasse 2000)
- Time to progression - assessed from date of randomisation to
date of objective disease progression, RECIST
- Quality of life
- Patient satisfaction
- Adverse events - graded according to the National Cancer In-
stitute Common Toxicity Criteria (NCI CTEP 1999)or World
Health Organisation Criteria
Search methods for identification of studies
We will use the Cochrane Lung Cancer Group methods.
Trials will be electronically for searched using MEDLINE (1966
to present), EMBASE (1966 to present) and the Cochrane Central
Register of Controlled Trials (CENTRAL). We have designed the
following search strategies for the mentioned databases:
MEDLINE (OVID):
1 RANDOMIZED CONTROLLED TRIAL.pt.
2 CONTROLLED CLINICAL TRIAL.pt.
3 RANDOMIZED CONTROLLED TRIALS.sh.
4 RANDOM ALLOCATION.sh.
5 DOUBLE BLIND METHOD.sh.
6 SINGLE BLIND METHOD.sh.
7 or/1 6
8 ANIMALS.sh. not HUMANS.sh.
9 7 not 8
10 CLINICAL TRIAL.pt.
11 exp CLINICAL TRIALS/
12 (clin$ adj25 trial$).ti,ab.
13 ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or
mask$)).ti,ab.
14 PLACEBOS.sh.
15 placebo$.ti,ab.
16 random$.ti,ab.
17 RESEARCH DESIGN.sh.
18 or/10 17
19 18 not 8
20 19 not 9
21 COMPARATIVE STUDY.sh.
22 exp EVALUATION STUDIES/
23 FOLLOW UP STUDIES.sh.
24 PROSPECTIVE STUDIES.sh.
25 (control$ or prospectiv$ or volunteer$).ti,ab.
26 or/21 25
27 26 not 8
28 27 not (9 or 20)
29 9 or 20 or 28
30 exp Lung Neoplasms/
31 exp Carcinoma, Non-Small-Cell Lung/
32 Non Small Cell.ti,ab.
33 NSCLC.ti,ab.
34 or/30-33
35 gefitinib.mp OR ZD1839.mp OR ZD 1839.mp OR
Iressa.ti,ab
36 exp Receptor, Epidermal Growth Factor/ai [Antagonists & In-
hibitors]
37 35 or 36
38 34 and 37
39 29 and 38
CENTRAL:
1 LUNG-NEOPLASMS*:ME
2 CARCINOMA-NON-SMALL-CELL-LUNG*.ME
3 ((LUNG OR PULMON*) AND (NEOPLAS* OR CANCER
OR CARCINOMA*))
4 (#1 OR #2 OR #3)
5 GEFITINIB OR ZD 1839 OR ZD1839 OR IRESSA
6 (#4 AND #5)
EMBASE (OVID):
1 Clinical trial/
2 Randomized controlled trial/
3 Randomization/
4 Single blind procedure/
5 Double blind procedure/
6 Crossover procedure/
7 Placebo/
8 Randomi?ed controlled trial$.tw.
9 Rct.tw.
10 Random allocation.tw.
11 Randomly allocated.tw.
12 Allocated randomly.tw.
13 (allocated adj2 random).tw.
14 Single blind$.tw.
15 Double blind$.tw.
16 ((treble or triple) adj (blind$).tw.
17 Placebo$.tw.
18 Prospective study/
19 Or/1-18
20 Case study/
21 Case report.tw.
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22 Abstract report/ or letter/
23 Or/20-22
24 19 not 23
25 exp Lung Cancer/
26 exp Lung non Small Cell Cancer/
27 non small cell.ti,ab.
28 NSCLC.ti,ab.
29 25 or 26 or 27 or 28
30 gefitinib.mp. or exp GEFITINIB/
31 (ZD1839 or ZD 1839).mp. or Iressa.ti,ab.
32 30 or 31
33 29 and 32
34 24 and 33
The authors will also screen reference lists of included and ex-
cluded studies, attempt to contact authors of relevant studies and
examine registers of ongoing trials (clinicaltrials.gov and Current
Controlled Trials) in order to locate all significant published and
unpublished data.
Data collection and analysis
Two authors will extract data independently from the included
papers. The following information will be sought from each trial:
Study details
-Year of publication
-Number of people randomised and analysed per arm
For population included
-Age, sex, race/ethnicity
-Staging
-Histological cell type
-Performance status
-Previous treatment, includingprevious exposure to chemotherapy
Type of intervention
-Dose of gefitinib and period of use
-Any other chemotherapeutic agents used
Results of intervention
-Time to death (time to event analysis)
-Median survival time per arm
-One-year survival rate per arm
-Tumour response - classified according to Response Evaluation
Criteria in Solid Tumours (RECIST), the revised version of the In-
ternational UnionAgainst Cancer/WHOcriteria (Therasse 2000)
-Overall response rate per arm
-Time to progression - assessed from date of randomisation to date
of objective disease progression, RECIST
-Quality of life
-Patient satisfaction
-Adverse events - graded according to the National Cancer In-
stitute Common Toxicity Criteria (NCI CTEP 1999) or WHO
toxicity guidelines
Statistical analysis
All analyses will be carried out on the basis of ’intention to treat’
and randomised patients will be analysed according to their ini-
tial allocation. Where appropriate continuous data for mean, SD
and number of subjects in each treatment and placebo arm are
available, data from trials will be combined using ReviewManager
4.2, generating a mean difference and 95% confidence interval.
Data from studies which examine the effect of different doses of
gefitinib will be analysed separately comparing each dosage with
placebo.
We will use a Fixed Effect mean difference for continuous vari-
ables. If data are reported on differentmetrics, we will apply a stan-
dardised mean difference (SMD), which expresses differences as
standard deviation units. Proportional outcomes, such as propor-
tion who survived, will be summarised using an odds ratio. The
Mantel-Haenszel method will be used to combine estimates of
the odds ratios. Hazard ratios will be calculated for data presented
as survival curves. Time to event analysis will also be performed.
Tests for heterogeneity will be performed using Review Manager
using I2 with a threshold of greater than 50%.
Subgroup analysis of the effect of gender, age, disease stage, WHO
performance status, weight loss, disease measurability, histology
and race on survival will be carried out. Included trials will also be
subject to a sensitivity analysis based on quality to assess the effect
of these studies on their reported outcomes. A random effects
model will also applied as part of sensitivity analysis.
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Date Event Description
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H I S T O R Y
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C O N T R I B U T I O N S O F A U T H O R S
Esther Sim, Ian Yang, and Kwun Fong designed the review strategy, and selected the studies for inclusion. Esther Sim and Ian Yang
extracted, entered and analysed the data. All reviewers prepared the review and approved the final version of the review.
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D E C L A R A T I O N S O F I N T E R E S T
* KF is an Investigator for a clinical trial of gefitinib for lung cancer (Astra Zeneca international trial) - funding received by the Hospital
funds the clinical trial and the employment of a trials nurse.
* KF’s laboratory has also undertaken contract research for a clinical study looking at immunohistochemistry of certain proteins in lung
cancer for Novartis - funding received will go to the Project and employment of Research staff for the Project.
* KF was previously offered an honorarium from a pharmaceutical company for attending an one-off Advisory Board Meeting; this
was not accepted and asked to be given to a charity.
* KF has received occasional pens, pads and minor stationery from Industry. KF has occasionally attended/spoken at meetings organised
by pharmaceutical companies where meals/travel costs would be sponsored.
* KF organises theQueensland LungCancer InterestGroupMeeting (2-3meetings per year, a teleconferencemeetingwhich is supported
by Eli Lilly. KF has/is also involved in organising and attending professional meetings including those run by the Thoracic Society of
Australia and New Zealand, Asia-Pacific Society of Respirology, Australian Lung Cancer Conference, IASLC, where some sponsorhsip
is usually provided by Industry.
* KFis involved with the Australian Lung Foundation’s Lung Cancer Cooperative Group (not-for-profit, public benevolent institution
)(www.lungnet.org.au) and its activities which includes promotion of Cochrane reviews. The ALF receives support from pharmaceutical
companies. KF is current Chair of the Australian Lung Cancer trials Group which receives some support funding from pharmaceutical
companies
* IY declares that he has received travel and accommodation sponsorship several times to speak at or participate in educational meetings,
which have been organised by an independent organising committee and sponsored by industry. He has accepted hospitality in
connection with evening professional educational meetings organised by pharmaceutical companies. He has occasionally received gifts
of small value such as pens and stationery from industry.
* IY is involved with the National COPD Executive of the Australian Lung Foundation (not-for-profit, public benevolent institution)
(www.lungnet.org.au) which receives some support from pharmaceutical companies.
* IY has/is also involved in organising and participating in professional scientific meetings including those organised by the Thoracic
Society of Australia and New Zealand, where some sponsorship is usually provided by industry.
* IY declares that he has not received consultancy fees or honoraria from pharmaceutical companies, and has not acted as a member of
advisory boards for pharmaceutical companies
*RBparticipated in anEli-Lilly sponsorednational lung cancer consultative group from1996-1999, receiving travel and accommodation
expenses. Consultancy fees were donated to University of Queensland biomedical research programmes.
* RB has received pharmaceutical company sponsored items, meals, and travel expenses associated with attendance at scientific meetings
including Australian Lung Cancer Conference and Thoracic Society of Australia and New Zealand.
* RB is a current member of the Australian Lung Foundation’s Lung Cancer Consultative Group which receives financial sponsorship
from a number of pharmaceutical companies.
* ES in the recipeint of a 2007 Australian Lung Foundation/Lung Cancer Consultative Group Cochrane Review Scholarship
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S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• The Australian Lung Foundation/Lung Cancer Consultative Group Cochrane Review Scholarship (ES), Australia.
• National Health and Medical Research Council (IY, KF, RB), Australia.
• Australian Lung Foundation Lung Consultative Group (IY, KF,RB), Australia.
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